A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Breakthrough study could lead to new treatments as experts explore how skin fungi trigger debilitating skin condition ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

A team of researchers led by the University of Exeter have been awarded a £3.3 million grant by the Medical Research Council ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

A team led by the University of Exeter, and including researchers from King's College London, has been awarded a £3.3 million ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...